Sunday Mar 22, 2026

Episode 2 - Patch - The CELEBRATE Trial

Patch Episode: Bridging the STEMI Gap with Zalunfiban (The CELEBRATE Trial)

Episode Description: The prehospital management of ST-Elevation Myocardial Infarction (STEMI) has evolved immensely, but we still face a major physiological roadblock: the delayed onset of oral P2Y12 inhibitors like ticagrelor. By the time our patients reach the cath lab, we are often racing our own medications. In this "Patch" episode, we explore a potential paradigm shift. We break down the newly published CELEBRATE trial and look at zalunfiban, a rapid subcutaneous glycoprotein IIb/IIIa inhibitor that aims to initiate the reperfusion cascade right in the patient's living room.

In This Episode, We Cover:

  • The Pharmacological Lag: Why oral antiplatelets fall short in the acute, sympathetic-overdrive state of a STEMI.

  • A New Approach to GPIs: How zalunfiban bypasses the gut with a rapid subcutaneous injection, achieving near-complete platelet inhibition in just 15 minutes.

  • The CELEBRATE Trial Breakdown: We dive into the methodology and the impressive results, including an NNT of just 29 for major adverse cardiac events and significant improvements in pre-cath TIMI flow.

  • The QA Perspective: A critical look at the bleeding risks, balancing the minor increase in nuisance bleeding against the lack of major intracranial or GI hemorrhages.

  • Operationalizing the Data: How this drug fits into direct-to-PCI pathways, its contraindications alongside prehospital fibrinolysis (like TNK), and what it means for your next shift.

References & Further Reading:

The medicine starts with you. Own the roadside, and I'll catch you on the next call.

Comment (0)

No comments yet. Be the first to say something!

Copyright 2022 All rights reserved.

Podcast Powered By Podbean

Version: 20241125